Advantages and challenges of oestrogen-free hormonal contraception

References

• United Nations. World Contraceptive Use 2007. 2008. Available at: http://www.un.org/esa/population/publications/contraceptive2007/contraceptive2007.htm [Last accessed 3 November 2009]
   Google Scholar
• Boyce J, Fawcett JW, Noall EW. Coronary thrombosis and Conovide. Lancet 1963;1:111
   PubMed Web of Science ®Google Scholar
• Jick H, Dinan B, Herman R, et al. Myocardial infarction and other vascular diseases in young women. Role of estrogens and other factors. JAMA 1978;240:2548-52
   PubMed Web of Science ®Google Scholar
• Mann JI, Vessey MP, Thorogood M, et al. Myocardial infarction in young women with special reference to oral contraceptive practice. Br Med J 1975;2:241-5
   PubMed Web of Science ®Google Scholar
• Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 1997;78:1-6
   PubMed Web of Science ®Google Scholar
• Sartwell PE, Stolley PD. Oral contraceptives and vascular disease. Epidemiol Rev 1982;4:95-109
   PubMed Web of Science ®Google Scholar
• Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981;305:612-18
   PubMed Web of Science ®Google Scholar
• Thorogood M, Vessey MP. An epidemiologic survey of cardiovascular disease in women taking oral contraceptives. Am J Obstet Gynecol 1990;163:274-81
   PubMed Web of Science ®Google Scholar
• Ahrendt HJ, Karck U, Pichl T, et al. The effects of an oestrogen-free, desogestrel-containing oral contraceptive in women with cyclical symptoms: results from two studies on oestrogen-related symptoms and dysmenorrhoea. Eur J Contracept Reprod Health Care 2007;12:354-61
   PubMed Web of Science ®Google Scholar
• Fischer MA. Implanon: a new contraceptive implant. J Obstet Gynecol Neonatal Nurs 2008;37:361-8
   PubMed Web of Science ®Google Scholar
• Rowlands S. New technologies in contraception. Br J Obstet Gynaecol 2009;116:230-9
   Google Scholar
• Pfizer Inc. Depo-Provera Contraceptive Injection. Patient Information, US. 2006. Available at: http://media.pfizer.com/files/products/ppi_depo_provera_contraceptive.pdf [Last accessed 3 November 2009]
   Google Scholar
• McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994;50:S1-195
   PubMed Web of Science ®Google Scholar
• Milsom I, Korver T. Ovulation incidence with oral contraceptives: a literature review. J Fam Plann Reprod Health Care 2008;34:237-46
   PubMed Web of Science ®Google Scholar
• Trussell J, Hatcher RA, Cates W Jr, et al. Contraceptive failure in the United States: an update. Stud Fam Plann 1990;21:51-4
   PubMed Web of Science ®Google Scholar
• Chi I. The safety and efficacy issues of progestin-only oral contraceptives – an epidemiologic perspective. Contraception 1993;47:1-21
   PubMed Web of Science ®Google Scholar
• Korver T, Klipping C, Heger-Mahn D, et al. Maintenance of ovulation inhibition with the 75 µg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-h delays in tablet intake. Contraception 2005;71:8-13
   PubMed Web of Science ®Google Scholar
• Rice CF, Killick SR, Dieben T, et al. A comparison of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel 30 micrograms daily. Hum Reprod 1999;14:982-5
   PubMed Web of Science ®Google Scholar
• Collaborative Study Group on the Desogestrel-containing Progestogen-only pill. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Eur J Contracept Reprod Health Care 1998;3:169-78
   PubMedGoogle Scholar
• Grimes DA, Lopez LM, O'Brien PA, et al. Progestin-only pills for contraception. Cochrane Database Syst Rev (Online) 2010:CD007541
   Google Scholar
• What do your patients really think about the pill? Contracept Rep 1995;6:8
   Google Scholar
• Peipert JF, Gutmann J. Oral contraceptive risk assessment: a survey of 247 educated women. Obstet Gynecol 1993;82:112-17
   PubMed Web of Science ®Google Scholar
• Loder EW, Buse DC, Golub JR. Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review. Am J Obstet Gynecol 2005;193:636-49
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Hormone-related headache. Med Clin North Am 2001;85:1017-35
   PubMed Web of Science ®Google Scholar
• Hatcher RA, Guillebaud J. The pill: combined oral contraceptives. In: Hatcher RA et al. (eds.) Contraceptive Technology, 17th edn. New York: Ardent Media, Inc., 1998:405-60
   Google Scholar
• Oddens BJ, Arnolds HT, Van Maris MG, et al. The dynamics of oral contraceptive use in The Netherlands 1990–1993. Adv Contracept 1994;10:167-74
   PubMedGoogle Scholar
• Ahrendt HJ, Apetauer I. Improvement of oestrogen-related symptoms with a desogestrel-only contraceptive among women who experienced oestrogen-related symptoms using combined oral contraceptives. Eur J Contracept Reprod Health Care 2008;13:102-3
   Google Scholar
• Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev (Online) 2008:CD003987
   Google Scholar
• Oddens BJ, Visser AP, Vemer HM, et al. Contraceptive use and attitudes in Great Britain. Contraception 1994;49:73-86
   PubMed Web of Science ®Google Scholar
• Dawood MY. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol 2006;108:428-41
   PubMed Web of Science ®Google Scholar
• Bieglmayer C, Hofer G, Kainz C, et al. Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol 1995;9:307-12
   PubMed Web of Science ®Google Scholar
• Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev (Online) 2001:CD002120
   Google Scholar
• Rosenwaks Z, Seegar-Jones G. Menstrual pain: its origin and pathogenesis. J Reprod Med 1980;25:207-12
   PubMed Web of Science ®Google Scholar
• Hendrix SL, Alexander NJ. Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception 2002;66:393-9
   PubMed Web of Science ®Google Scholar
• Edelman AB, Gallo MF, Jensen JT, et al. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev (Online) 2005:CD004695
   Google Scholar
• Lurie S, Borenstein R. The premenstrual syndrome. Obstet Gynecol Surv 1990;45:220-8
   PubMedGoogle Scholar
• Halbreich U. The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology 2003;28:55-99
   Web of Science ®Google Scholar
• Sundström Poromaa I, Smith S, Gulinello M. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Womens Ment Health 2003;6:23-41
   PubMedGoogle Scholar
• Straneva PA, Maixner W, Light KC, et al. Menstrual cycle, beta-endorphins, and pain sensitivity in premenstrual dysphoric disorder. Health Psychol 2002;21:358-67
   PubMed Web of Science ®Google Scholar
• Epperson CN, Haga K, Mason GF, et al. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 2002;59:851-8
   PubMed Web of Science ®Google Scholar
• Andersch B, Hahn L. Premenstrual complaints II. Influence of oral contraceptives. Acta Obstet Gynecol Scand 1981;60:579-83
   PubMed Web of Science ®Google Scholar
• Kutner SJ, Brown WL. Types of oral contraceptives, depression, and premenstrual symptoms. J Nerv Ment Dis 1972;155:153-62
   PubMed Web of Science ®Google Scholar
• Bancroft J, Rennie D. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and other symptoms. J Psychosom Res 1993;37:195-202
   PubMed Web of Science ®Google Scholar
• Graham CA, Sherwin BB. The relationship between mood and sexuality in women using an oral contraceptive as a treatment for premenstrual symptoms. Psychoneuroendocrinology 1993;18:273-81
   PubMed Web of Science ®Google Scholar
• Hellberg D, Claesson B, Nilsson S. Premenstrual tension: a placebo-controlled efficacy study with spironolactone and medroxyprogesterone acetate. Int J Gynaecol Obstet 1991;34:243-8
   PubMed Web of Science ®Google Scholar
• Magill PJ. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. Progesterone Study Group. Br J Gen Pract 1995;45:589-93
   PubMed Web of Science ®Google Scholar
• Couturier EG, Bomhof MA, Neven AK, et al. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 2003;23:302-8
   PubMed Web of Science ®Google Scholar
• Allais G, Benedetto C. Update on menstrual migraine: from clinical aspects to therapeutical strategies. Neurol Sci 2004;25(Suppl. 3):S229-31
   PubMedGoogle Scholar
• Headache Classification Subcommittee of the International Headache Society (IHS). The International Classification of Headache Disorders, 2nd edn (ICHD II). Cephalalgia 2004;24(Suppl. 1):1-160
   Google Scholar
• Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261-6
   PubMed Web of Science ®Google Scholar
• Ahrendt HJ, Kleinschmidt S, Kropf S, et al. Präventive Wirkung hormoneller Kontrazeptiva im Langzyklus bei menstrueller Migräne. Frauenarzt 2007;48:2-7
   Google Scholar
• Ageno W, Becattini C, Brighton T, et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008;117:93-102
   PubMed Web of Science ®Google Scholar
• Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008;83:97-102
   PubMed Web of Science ®Google Scholar
• Pomp ER, le Cessie S, Rosendaal FR, et al. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007;139:289-96
   PubMed Web of Science ®Google Scholar
• Shapiro S. Oral contraceptives, hormone therapy and cardiovascular risk. Climacteric 2008;11:355-63
   PubMed Web of Science ®Google Scholar
• Allais G, Gabellari IC, De Lorenzo C, et al. Oral contraceptives in migraine. Expert Rev Neurother 2009;9:381-93
   PubMed Web of Science ®Google Scholar
• Allais G, Gabellari IC, Mana O, et al. Migraine and stroke: the role of oral contraceptives. Neurol Sci 2008;29(Suppl. 1):S12-S14
   Google Scholar
• Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. UK Medical Eligibility Criteria for Contraceptive Use (UKMEC 2005/2006). London: Faculty of Family Planning and Reproductive Health Care, 2006
   Google Scholar
• Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344-54
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7
   PubMed Web of Science ®Google Scholar
• van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case–control study. BMJ 2009;339:b2921
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, McClish DK, Essah PA, et al. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005;90:3863-70
   PubMed Web of Science ®Google Scholar
• Chan WS, Ray J, Wai EK, et al. Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch Intern Med 2004;164:741-7
   PubMed Web of Science ®Google Scholar
• Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA 2000;284:72-8
   PubMed Web of Science ®Google Scholar
• Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001;345:1787-93
   PubMed Web of Science ®Google Scholar
• International Collaborative Post-marketing Surveillance of Norplant. Post-marketing surveillance of Norplant contraceptive implants: II. Non-reproductive health. Contraception 2001;63:187-209
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case–control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998;57:315-24
   PubMed Web of Science ®Google Scholar
• Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999;354:1610-11
   PubMed Web of Science ®Google Scholar
• Schindler AE. Differential effects of progestins on hemostasis. Maturitas 2003;46(Suppl. 1):S31-S31
   PubMed Web of Science ®Google Scholar
• Vieira CS, Ferriani RA, Garcia AA, et al. Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. Hum Reprod 2007;22:2196-201
   PubMed Web of Science ®Google Scholar
• Porter C, Rees MC. Bleeding problems and progestogen-only contraception. J Fam Plann Reprod Health Care 2002;28:178-81
   PubMed Web of Science ®Google Scholar
• Organon Laboratories Limited. Cerazette: Summary of product characteristics. 2008. Available at: http://emc.medicines.org.uk/medicine/10098 [Last accessed 3 November 2009]
   Google Scholar